Search alternatives:
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mean decrease » a decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
mean decrease » a decrease (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
-
141
-
142
-
143
Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.
Published 2021“…Shaded regions correspond to the standard error of the mean and dashed lines correspond to the peaks of each CAP, labeled with the same colors as the CAPs. …”
-
144
-
145
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
146
-
147
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
148
-
149
-
150
Base-case results.
Published 2024“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”
-
151
Base-case analysis.
Published 2023“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160